256 related articles for article (PubMed ID: 2568174)
21. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
22. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
23. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
Weiskirch LM; Bar-Dagan Y; Mokyr MB
Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116
[TBL] [Abstract][Full Text] [Related]
25. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
26. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
Gorelik L; Prokhorova A; Mokyr MB
Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
[TBL] [Abstract][Full Text] [Related]
27. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression.
Kalinichenko VV; Mokyr MB; Graf LH; Cohen RL; Chambers DA
J Immunol; 1999 Sep; 163(5):2492-9. PubMed ID: 10452985
[TBL] [Abstract][Full Text] [Related]
28. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
29. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.
Bartik MM; Ahn MC; Baumgartel BA; Hendricks RL; Mokyr MB
Cancer Immunol Immunother; 1990; 32(3):143-53. PubMed ID: 2289208
[TBL] [Abstract][Full Text] [Related]
30. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
31. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.
Ben-Efraim S; Bocian RC; Mokyr MB; Dray S
Cancer Immunol Immunother; 1983; 15(2):101-7. PubMed ID: 6553510
[TBL] [Abstract][Full Text] [Related]
32. Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity.
Ben-Efraim S; Shoval S; Gal T; Ophir R
Anticancer Res; 1986; 6(4):801-5. PubMed ID: 2944475
[TBL] [Abstract][Full Text] [Related]
33. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
Barker E; Mokyr MB
Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
[TBL] [Abstract][Full Text] [Related]
34. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
35. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
Mokyr MB; Kalinichenko T; Gorelik L; Bluestone JA
Cancer Res; 1998 Dec; 58(23):5301-4. PubMed ID: 9850053
[TBL] [Abstract][Full Text] [Related]
36. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
[TBL] [Abstract][Full Text] [Related]
37. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity.
Jovasevic VM; Gorelik L; Bluestone JA; Mokyr MB
J Immunol; 2004 Feb; 172(3):1449-54. PubMed ID: 14734721
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
Rubin M; Mokyr MB
Cancer Immunol Immunother; 1993; 36(1):37-44. PubMed ID: 8422666
[TBL] [Abstract][Full Text] [Related]
39. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
Laude M; Siessmann KL; Mokyr MB; Dray S
Cancer Res; 1991 Sep; 51(17):4516-22. PubMed ID: 1873795
[TBL] [Abstract][Full Text] [Related]
40. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma.
Cook-Mills JM; Mokyr MB; Cohen RL; Perlman RL; Chambers DA
Cancer Immunol Immunother; 1995 Feb; 40(2):79-87. PubMed ID: 7882386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
